DiscGenics to Study Cell Therapy for Degenerative Disease

DiscGenics IDCT Injection

DiscGenics gained acceptance from FDA for the clinical protocols and Chemistry, Manufacturing, and Controls clinical development plan for the Phase III clinical program of its allogeneic, injectable disc progenitor cell therapy (IDCT) for lumbar degenerative disc disease (DDD), allowing the study to proceed.

The Phase III clinical program...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0